Fundsmith LLP
CPRX

Fundsmith LLP’s Catalyst Pharmaceutical CPRX Stock Holding History

Fundsmith LLP’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.9M Sell
844,887
-2,518,920
-75% -$60M 0.16% 27
2025
Q4 		$78.5M Hold
3,363,807
– – 0.46% 25
2025
Q3 		$66.3M Buy
3,363,807
+654,721
+24% +$13.5M 0.33% 31
2025
Q2 		$58.8M Buy
2,709,086
+557,812
+26% +$13.2M 0.26% 32
2025
Q1 		$52.2M Buy
+2,151,274
New +$48.4M 0.24% 35

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fundsmith LLP's CPRX Position: Q1 2026 in Review

Fundsmith LLP reduced its Catalyst Pharmaceutical (CPRX) stake by 75% in Q1 2026, selling an estimated $60M and leaving 844,887 shares worth $20.9M. The position accounts for 0.16% of the portfolio, ranked #27.

Fundsmith LLP first reported a position in CPRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $78.5M in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Fundsmith LLP held 844,887 shares of Catalyst Pharmaceutical worth $20.9M as of Q1 2026.
  • Fundsmith LLP sold 2,518,920 Catalyst Pharmaceutical shares in Q1 2026, an estimated $60M.
  • Catalyst Pharmaceutical made up 0.16% of Fundsmith LLP's portfolio in Q1 2026, its #27 holding.
  • Fundsmith LLP first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 5 quarters since.
  • Fundsmith LLP's Catalyst Pharmaceutical position peaked at $78.5M in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Fundsmith LLP's 13F filing for Q1 2026, filed 15 May 2026.